A recent study has reported faster healing of periapical tissues when a TNFα antibody was used as an anti-inflammatory therapy in inflammatory bowel disease patients, who are considered to be at high risk of therapy-resistant AP12. The gene discussed is TNF; the disease is inflammatory bowel disease.